Value
5.6/10data confidence 60%| Component | Sub-score |
|---|---|
| P/E | 10.0 |
| P/S | 6.8 |
| EV/EBITDA | 0.0 |
APMD · Why this verdict
Why Apnimed (APMD) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.5/10
ConfidenceHIGH
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
Apnimed is a speculative biotech trading 54% below its 52-week high with heavy insider buying of $5.2M, but revenue is declining 29%, the sole earnings report was a miss and business quality is weak.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Business quality is weak, with a 3/9 Piotroski F-Score, operating margin scored 0.0 and no competitive moat, plus leverage penalized at a debt-to-equity of 1.3. Quality breakdown | Piotroski F-Score improves above 5 over the next 12 months. | →Stable |
| CounterA leveraged, loss-making biotech with a weak financial score depends on outside funding to reach commercialization. | ||
Insiders bought about $5.2M of stock over 90 days (0.762% of market cap), a heavy insider-buying signal with institutions accumulating. Insider | Insider buying continues or at least no material selling over the next 2 quarters. | ↓Deteriorating |
| CounterInsider purchases in a biotech after a 54% drawdown may reflect hope rather than clinical knowledge and can be wrong. | ||
Revenue is declining 29%, scoring 0.0 on growth, with quarterly revenue swinging from $84.8M to $12.1M. Growth breakdown | Revenue growth turns positive above 0% YoY as milestone or product revenue builds. | →Stable |
| CounterQuarterly revenue is lumpy and partly provisional, so the trend may reflect timing of milestone payments rather than operations. | ||
The only reported quarter was a 22.5% EPS miss (-$0.42 versus -$0.34), with the next report due 2026-11-11. Earnings | EPS loss narrows to better than -$0.34 at the November report. | ↑Improving |
| CounterWith a single quarter of data and a 22.5% miss, there is no evidence yet of estimate reliability. | ||
The stock sits 54% below its 52-week high with momentum scored 4.2 and falling on-balance volume, and technical resistance at $21.67 is 32.1% above the $16.40 price. Targets | The price holds above the $15.68 stop and momentum rises above 4.5. | Tripped↓Deteriorating |
| CounterDistribution volume and a deep drawdown show persistent selling, and a break of $15.68 would extend the decline. | ||
Business quality is weak, with a 3/9 Piotroski F-Score, operating margin scored 0.0 and no competitive moat, plus leverage penalized at a debt-to-equity of 1.3.
→StableQuality breakdown
- Expectation
- Piotroski F-Score improves above 5 over the next 12 months.
CounterA leveraged, loss-making biotech with a weak financial score depends on outside funding to reach commercialization.
Insiders bought about $5.2M of stock over 90 days (0.762% of market cap), a heavy insider-buying signal with institutions accumulating.
↓DeterioratingInsider
- Expectation
- Insider buying continues or at least no material selling over the next 2 quarters.
CounterInsider purchases in a biotech after a 54% drawdown may reflect hope rather than clinical knowledge and can be wrong.
Revenue is declining 29%, scoring 0.0 on growth, with quarterly revenue swinging from $84.8M to $12.1M.
→StableGrowth breakdown
- Expectation
- Revenue growth turns positive above 0% YoY as milestone or product revenue builds.
CounterQuarterly revenue is lumpy and partly provisional, so the trend may reflect timing of milestone payments rather than operations.
The only reported quarter was a 22.5% EPS miss (-$0.42 versus -$0.34), with the next report due 2026-11-11.
↑ImprovingEarnings
- Expectation
- EPS loss narrows to better than -$0.34 at the November report.
CounterWith a single quarter of data and a 22.5% miss, there is no evidence yet of estimate reliability.
The stock sits 54% below its 52-week high with momentum scored 4.2 and falling on-balance volume, and technical resistance at $21.67 is 32.1% above the $16.40 price.
Tripped↓DeterioratingTargets
- Expectation
- The price holds above the $15.68 stop and momentum rises above 4.5.
CounterDistribution volume and a deep drawdown show persistent selling, and a break of $15.68 would extend the decline.
Per-dimension breakdown
Quality
5.2/10data confidence 71%| Component | Sub-score |
|---|---|
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Current ratio | 7.8 |
| Moat | 4.8 |
| Piotroski F | 3.3 |
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 3/9
Growth
0.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 0.0 |
- ▸Declining revenue: -29%
Momentum
2.3/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.5 |
| MACD | 0.6 |
| OBV | 1.0 |
| MA position | 2.5 |
| Volume | 4.0 |
- ▸Volume distribution (falling OBV)
Sentiment
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.0 |
| Analyst rating | 5.0 |
| Price target | 10.0 |
- ▸Analyst upside: 255%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 8.1 |
| quality rank | 10.0 |
| growth rank | 2.9 |
- ▸Attractive P/E vs peers
- ▸Best-in-class margins
Technical
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 10.0 |
| support resistance | 9.5 |
| 52w position | 0.0 |
Risk (lower is worse)
4.1/10data confidence 60%| Component | Sub-score |
|---|---|
| days to cover | 8.0 |
| volatility | 0.0 |
| debt equity | 4.4 |
Catalyst
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 5.0 |
- ▸Earnings in 5 days
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (5)
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:2.3<4.5
- EARNINGS_PROXIMITY:5d<=7d
Warning (1)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
Reward-to-Risk
0.00
Upside
+38.4%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -60% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The F-path SELL output reflects an overall score of 4.0 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Insider at 7.3) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( MOMENTUM:2.3<4.5, EARNINGS_PROXIMITY:5d<=7d) reinforce the read. Current asymmetry R:R is 0.00 — supplementary context, not the trigger for this path.
The strongest dimensions are Insider at 7.3, Sentiment at 6.5, and Technical at 6.5; the weakest are Growth at 0.0, Momentum at 2.3, and Catalyst at 3.0. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Heavy Insider Buying
Trip ifNet insider selling exceeds $2M over a 90-day period.
- P2Declining Revenue Lumpy
Trip ifRevenue growth stays below -20% YoY for 2 consecutive quarters.
- P3Weak Quality No Moat
Trip ifPiotroski F-Score falls below 2 from current 3.
- P4Earnings Miss And Binary Report
Trip ifEPS surprise stays below 0% for 2 consecutive quarters.
- P5Deep Drawdown Weak MomentumTripped
Trip ifPrice falls below the $15.68 stop-loss level.